Fam-trastuzumab deruxtecan-nxki (Intravenous)
Medically reviewed by Drugs.com. Last updated on Jan 23, 2022.
Interstitial Lung Disease (ILD) and pneumonitis, including fatal cases, have been reported. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and the need to immediately report symptoms. Exposure to fam-trastuzumab deruxtecan-nxki during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception .
Commonly used brand name(s)
In the U.S.
- Enhertu
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Antibody Drug Conjugate
Uses for fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki injection is used to treat HER2-positive metastatic (cancer that has spread to other parts of the body) breast cancer or whose cancer cannot be removed with surgery in patients who have previously received an anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for early-stage breast cancer.
Fam-trastuzumab deruxtecan-nxki injection is also used to treat HER-2 positive metastatic (cancer that has spread to other parts of the body) or locally advanced (cancer that has spread to areas near the stomach) stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma in patients who have previously received trastuzumab-based regimen.
HER2 protein is produced by some tumors. Fam-trastuzumab deruxtecan-nxki interferes with the growth of this protein which also prevents tumor growth. The tumor cells will then be destroyed by the body.
Fam-trastuzumab deruxtecan-nxki is to be given only by or under the immediate supervision of your doctor.
Before using fam-trastuzumab deruxtecan-nxki
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For fam-trastuzumab deruxtecan-nxki, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to fam-trastuzumab deruxtecan-nxki or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of Enhertu® in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Enhertu® in the elderly. However, elderly patients are more likely to have unwanted side effects which may require caution in patients receiving fam-trastuzumab deruxtecan-nxki.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh..
